Method to Detect the Onset and to Monitor the Recurrence of Chronic Graft Versus Host Disease in Transplantation Patients
AssigneeThe Board of Trustees of the Leland University Junior University
InventorsDavid B. Miklos, Bita Sahaf, Leonore A. Herzenberg
Life of this patent
Estimating the term…
Abstract
The described invention comprises a method for detecting the onset or monitoring the recurrence of chronic graft versus host disease (cGVHD) in a transplantation patient. The method comprises isolating peripheral blood mononuclear cells (PBMCs) from the transplantation patient and analyzing the isolated PBMCs to detect a biomarker specific for a donor cell. The detection of the biomarker is indicative of the onset or recurrence of cGVHD in the transplantation patient.
Claims30
A method for warning of onset of chronic graft versus host disease (cGvHD) prior to appearance of symptoms of cGvHD in a patient following a hematopoietic cell transplantation therapy with a hematopoietic cell allograft, comprising:
- (a) isolating peripheral blood mononuclear cells (PBMCs) from the patient at a time after the therapy;
- (b) analyzing the isolated PBMCs, and specifically detecting a first biomarker expressed by circulating cells of the patient that reacts with a second biomarker expressed by genetically distinct cells,
- wherein the detecting of the cells that express the first biomarker indicates likely imminent onset of cGVHD in the patient;
- and
- (c) initiating immune therapy to mitigate symptoms of cGvHD resulting from the transplant.
A method for warning of recurrence of chronic graft versus host disease (cGvHD) prior to appearance of symptoms of cGvHD in a patient who, following hematopoietic cell transplantation therapy with a hematopoietic cell allograft, developed and was treated for cGvHD, which is in remission, comprising:
- (a) isolating peripheral blood mononuclear cells (PBMCs) from the patient at a time after the therapy;
- (b) analyzing the isolated PBMCs, and specifically detecting a first biomarker expressed by circulating cells of the patient that reacts with a second biomarker expressed by genetically distinct cells,
- wherein the detecting of the cells that express the first biomarker indicates likely imminent onset of cGvHD in the patient;
- and
- (c) initiating immune therapy to treat the recurrence of the cGvHD resulting from the transplant.
Dependencies are inferred from the claim text.